Saturday 17 October 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024. In the quarter to June 2026, revenue grew 14,590.2%, EPS fell 72.4% and free cash flow fell 56.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.83
0.03
+1.07%
Follow EVAX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 191.50 | 75.50 | 23.50 | 4.15 | 1.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 1,252.00 | 233.65 | 107.00 | 68.05 | 12.15 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 35 | 61 | 60 | 49 | 46 | 46 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.16 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 3 | 8 | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | (6) | (12) | (17) | (25) | (24) | (23) | (11) | (9) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (31,390.41) | (339.56) | (114.44) | |||||
| Net income | — | 0 | (6) | (11) | (15) | (25) | (23) | (22) | (11) | (8) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 3.12 | 1.17 | ||||
| Earnings | — | — | (0.34) | (40.29) | (48.50) | (63.00) | (49.00) | (40.47) | (9.85) | (1.00) | |||||
| Cash flow | — | — | (0.14) | (25.27) | (40.29) | (56.25) | (54.51) | (32.36) | (12.06) | (1.03) | |||||
| Capex | — | — | 0.00 | (0.22) | (0.60) | (3.49) | (0.62) | (0.16) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (0.14) | (25.49) | (40.89) | (59.74) | (55.13) | (32.52) | (12.06) | (1.04) | |||||
| Book value | — | — | (0.07) | 33.70 | 22.80 | 83.19 | 17.56 | (8.65) | (1.54) | 2.66 | |||||
| Shares, m | — | — | 14 | 0 | 0 | 0 | 0 | 1 | 1 | 6 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 2.84 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.78 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.33 | |||||
| EV/FCF | — | — | — | — | — | — | — | (3.61) | (0.32) | (0.47) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (7) | (12) | (22) | (26) | (18) | (13) | (7) | ||||
| Capex | — | — | 0 | 0 | 0 | (1) | 0 | 0 | — | 0 | |||||
| Free cash flow | — | — | (2) | (7) | (13) | (23) | (26) | (18) | (13) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (1) | 9 | 6 | 30 | 13 | 1 | 4 | 21 | ||||
| Total debt | — | — | 9 | 0 | 0 | 3 | 10 | 11 | 10 | 7 | |||||
| Net debt | — | — | 1 | (10) | (6) | (29) | (3) | 5 | 4 | (16) | |||||
| Shareholders’ equity | — | — | (1) | 9 | 7 | 32 | 8 | (5) | (2) | 17 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (129.91) | (114.25) | (130.31) | (94.12) | (74.51) | (126.74) | (83.29) | (37.69) | ||||
| ROIC | — | — | 0.00 | 0.00 | (846.00) | (442.73) | (311.38) | (5,979.80) | (421.78) | (608.14) | |||||
| ROE | — | — | (131.17) | (265.57) | (183.15) | (124.29) | (113.74) | (1,238.11) | 331.20 | (100.18) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Sep 2025
Charts ten years each
Evaxion A/S - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABVC ABVC BioPharma, Inc. | $24.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $23.9M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CYAD Celyad SA | $23.8M | — (loss-making) | — (loss-making) | — | n/m | +78.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLRZ Polyrizon Ltd. | $23.7M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| IMMP Prima BioMed Ltd | $23.7M | — (loss-making) | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.4M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | |
| ESLA Estrella Immunopharma, Inc. | $23.3M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| CNTX Context Therapeutics Inc. | $22.1M | — (loss-making) | — | — | n/m | −20.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QNTM Quantum Biopharma Ltd. | $21.9M | — (loss-making) | — (loss-making) | — | n/m | +5.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $23.7M | — | — | — | — | −7.37% | 50.00% | 0.00% |
Evaxion A/S - Sponsored ADR (EVAX) key facts
- Strength: Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024.
- Evaxion A/S - Sponsored ADR (EVAX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, EVAX traded at $2.83, a market capitalization of $23.4 million.
- Return on equity was −100.2% and debt-to-equity 0.71.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.54 (distress zone) for fiscal 2025.
Evaxion A/S - Sponsored ADR (EVAX) Latest News
No news at this impact. Lower the threshold for more.